DPP4 and diabetes mellitus: Targeting DPPIV with therapeutic inhibitors holds immense promise toward the mitigation of long-term cardiovascular and cerebrovascular risks, particularly in post-COVID-19 fatigue patients with comorbidities that include diabetes and hypertension.